

Governor Reynolds Signs HF2589 Into Law



From: Iowa DPH &lt;iowaDPH@public.govdelivery.com&gt;

Subject: Governor Reynolds Signs HF2589 Into Law

Having trouble viewing? [View this as a webpage](#)



6/29/2020

## Governor Reynolds Signs HF2589 Into Law, Expanding Iowa's Medical Cannabidiol Program

On June 29, 2020, Governor Kim Reynolds signed [HF2589](#) into law. It becomes effective on **July 1, 2020**.

This legislation includes multiple amendments to Iowa's Medical Cannabidiol Program, including:

- Removing the 3% THC limit on products, and replaces it with a '4.5g THC per 90-day' purchase limit.
  - Establishes exceptions to the 4.5g THC per 90-day purchase limit for the terminally ill
  - Or if the patient's healthcare practitioner certifies them for additional THC after the patient has participated in the program.
- Additional or amended conditions:
  - Amends 'untreatable pain' to 'chronic pain'
  - Adds post-traumatic stress disorder (PTSD)
  - Adds severe, intractable autism with self-injurious or aggressive behaviors.
- Additional Healthcare Practitioners:
  - Adds Physician Assistants (PAs), Advanced Registered Nurse Practitioners (ARNPs) and podiatrists to the list of health care practitioners that can certify patients for participation in the program.
- Making IDPH responsible for the issuance of registration cards, instead of the DOT.
- Dispensaries will be required to employ either a pharmacist or a pharmacy technician.
- Removes the felony disqualifiers for patients and primary caregivers having convictions related to a controlled substance.
- Removes the limit on the number of medical cannabidiol board meetings allowed each year.

These and other changes included in HF2589 will be implemented, or will be in the process of implementation, on July 1, 2020. The Office of Medical Cannabidiol will be providing further guidance and communications to its stakeholders on changes and alterations to processes shortly, as well as updates to the program's website at <https://idph.iowa.gov/omc>.

The Office of Medical Cannabidiol is here to support your understanding of these programmatic changes.